Pharmanutra SpA (PHN.MI) Stock Price

Pharmanutra SpA Price

Borsa Italiana·CLOSED
87.30
​
Market closed

Revenue has compounded at 17.5% per year over the past 10 years to 131.69 M EUR. Earnings per share have grown at 22.8% per year over the last 10 years. Pharmanutra SpA's net margin stands at 15.2%, down from 20.2% several years earlier. Pharmanutra SpA currently offers a dividend yield of about 1.15%. The payout ratio is around 48% of earnings. The dividend has grown at 17.2% per year over the past 7 years. Analysts set a median price target of 86.70 EUR, implying 0.7% below the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Pharmanutra SpA stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmanutra SpA business model & stock analysis

Pharmanutra SpA is an Italian company specialized in the research, development, and production of dietary supplements and medical devices. The company was founded in 1992 and is headquartered in Rome. Its mission is to combine the best of nature and science to provide the best possible healthcare for people. Pharmanutra invests in research and development to find innovative solutions for better healthcare. Its business model is based on research and development, production, and distribution. The company produces its products in Italy and aims to meet the highest quality standards. Pharmanutra offers a wide range of products in the areas of dietary supplements, medical devices, and clinical nutrition, tailored to the needs of customers. Overall, Pharmanutra is a specialized company focused on developing and manufacturing innovative healthcare products, with a history of research and development and collaborations with universities and research institutions. Its products are designed to meet the specific needs of patients and consumers.

Frequently asked questions about Pharmanutra SpA

The business model of Pharmanutra SpA revolves around producing and commercializing nutritional and dietary products. Pharmanutra SpA is a company that specializes in developing and marketing scientifically advanced food supplements, medical foods, and nutraceuticals. With a strong focus on research and innovation, Pharmanutra aims to provide high-quality products that contribute to the well-being and improve the health of individuals. Through strategic partnerships with healthcare professionals and a commitment to scientific excellence, Pharmanutra SpA strives to make a positive impact in the field of nutrition and healthcare.

Pharmanutra SpA is primarily active in the nutraceutical industry.

The main competitors of Pharmanutra SpA in the market include companies like Biogaia AB, Blackmores Limited, and Nestle S.A. They compete in the nutrition and healthcare industry, offering products that cater to various health needs. Despite facing stiff competition, Pharmanutra SpA has established a strong presence and reputation in the market, thanks to its high-quality and innovative offerings.

Pharmanutra SpA is a leading pharmaceutical company with a rich history and remarkable background. Founded in [year], the company has grown into a global provider of innovative health solutions. Pharmanutra SpA specializes in the development, manufacturing, and distribution of high-quality pharmaceutical products, catering to various medical needs. With a strong commitment to research and development, Pharmanutra SpA has emerged as a trusted name in the industry, consistently delivering effective and safe treatments. The company's dedication to cutting-edge technology, uncompromising quality standards, and customer-centric approach has established it as a frontrunner in the pharmaceutical sector, making Pharmanutra SpA a reliable choice for those seeking advanced healthcare solutions.

Pharmanutra SpA, a leading pharmaceutical company, has reached significant milestones in its journey. The company has successfully developed groundbreaking products and therapies, enhancing the healthcare industry. Pharmanutra SpA has exhibited remarkable growth and innovation, excelling in research and development to deliver high-quality healthcare solutions. Through strategic collaborations and partnerships, the company has expanded its global reach and gained recognition for its exceptional contributions to medical advancements. Pharmanutra SpA's commitment to excellence and its dedication to improving patient care have resulted in numerous accolades and industry awards. These milestones highlight the company's relentless pursuit of innovation and its unwavering commitment to improving the well-being of individuals worldwide.

Pharmanutra SpA is primarily present in various countries and regions, including Italy, its home country, as well as other European countries such as France, Germany, Spain, and the United Kingdom. Additionally, Pharmanutra SpA has expanded its presence internationally, reaching markets in North America, specifically the United States and Canada. With a global presence, Pharmanutra SpA continues to serve consumers and healthcare professionals with their innovative and high-quality nutraceutical products.

Pharmanutra SpA is a leading company in the pharmaceutical industry, representing strong values and a distinctive corporate philosophy. With a focus on innovation and scientific research, Pharmanutra is dedicated to improving the health and well-being of individuals. The company places great emphasis on quality and safety standards, ensuring that their products meet the highest industry regulations. Pharmanutra SpA also values sustainability and social responsibility, actively contributing to the communities they operate in. By combining excellence, integrity, and a customer-centric approach, Pharmanutra SpA remains committed to delivering innovative healthcare solutions that positively impact people's lives.

Analysts currently set an average price target of 83.98 EUR for the Pharmanutra SpA stock (median: 86.70 EUR), implying -2.1 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Pharmanutra SpA stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pharmanutra SpA to generate revenue of 159.83 M EUR and earnings per share of 2.61 EUR.

The Pharmanutra SpA share (PHN.MI) is listed on 6 stock exchanges, including: Frankfurt (761.F), München (761.MU), Düsseldorf (761.DU), Mailand (PHN.MI).

Pharmanutra SpA is a leading provider of innovative and high-quality dietary supplements, medical foods, and nutraceuticals. The company was founded in Italy in 1993 and is headquartered in Pisa. The company operates internationally with offices in France, Germany, England, Spain, and the USA. Pharmanutra is divided into several business divisions that have their own research and development departments, production facilities, and distribution channels. The main area is the development and production of functional foods and medical foods that meet the medical needs of various diseases and disorders. This includes products to support gastrointestinal tract, kidney, and liver function, as well as products for clinical nutrition. Another important business area is the production of dietary supplements that support optimal nutrient and vitamin intake. The focus here is on high-quality products that have high bioavailability and excellent tolerability. Pharmanutra mainly distributes its products through pharmacies, but also through online shops and direct sales channels. The customers include end consumers as well as doctors, hospitals, and clinics. The company operates a comprehensive quality management system in accordance with national and international standards such as GMP (Good Manufacturing Practice) and ISO 9001:2015. This ensures the monitoring and assurance of product quality and safety. A special focus of the company is on research and development of new products. The company collaborates closely with universities, specialists, and research institutes to develop innovative product ideas and test their effectiveness and safety. In summary, Pharmanutra is a leading provider of functional foods, medical foods, and dietary supplements. The company is divided into several business divisions that have their own research and development departments, production facilities, and distribution channels. With its high-quality and innovative products, the company focuses on improving people's health and well-being.

The expected revenue of Pharmanutra SpA is 159.83 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pharmanutra SpA is 24.84 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pharmanutra SpA is currently 33.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pharmanutra SpA stock.

The price-to-sales ratio (P/S) of Pharmanutra SpA is currently 5.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pharmanutra SpA stock.

The Eulerpool Quality Score for Pharmanutra SpA is 10/10.

The ISIN of Pharmanutra SpA is IT0005274094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pharmanutra SpA is A2DU6N. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pharmanutra SpA is PHN.MI. The ticker symbol is used to trade Pharmanutra SpA shares on the stock exchange.

Fair ValueTerminal
91.67 EUR
Over-/UndervaluationTerminal
Fairly valued
Industry
Personal Products
Number of shares
Employees
Revenue per Employee
2.44 M EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
EUR
Initial public offering
Jul 18, 2017
ISIN
IT0005274094
Cusip
T7S298129
Sedol
BF7LFB6
Market capitalization
838.87 M EURSmall Cap
52-Week Range
PEG
2.85
P/E ratio
P/Ee 2026
33.77
P/Ee 2027
26.41
P/Ee 2028
22.46
P/S
P/Se
5.20
EV/EBIT
27.74
P/B Ratio
11.76
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
21.77 %
Dividend
Dividend yield
1.15 %
Est. Dividend Yield
1.37 %
Payout Ratio
47.61 %
Dividend growth Ø5Y
11.07 %
Dividend payments per year
1
Dividend paid since
8 years
Dividend not reduced since
5 years
Dividend increased since
5 years
Dividend withholding tax
26.00 %
Last updated Nov 22, 2026, 3:41 AM

Pharmanutra SpA Peer Group

Pharmanutra SpA Ticker

DÜSSELDORF · 761.DUEURONEXT · PHN.MIFRANKFURT · 761.FMILAN · PHN.MIMILAN · PHN.MIMUNICH · 761.MU

Pharmanutra SpA FIGI

PHN:IM · BBG00H5FW2L0PHN2EUR:EO · BBG00H5H1L10PHN2EUR:XH · BBG00H5H1L47PHN2EUR:XF · BBG00H5H1L65PHN2EUR:XE · BBG00H5H1L83PHN2EUR:XJ · BBG00H5H1L92PHN2EUR:XL · BBG00H5H1LB9PHN2EUR:XG · BBG00H5H1LC8PHN2EUR:XO · BBG00H5H1LD7PHN2EUR:XS · BBG00H5H1LJ1PHN2EUR:XA · BBG00H5H1LK9PHN2EUR:E1 · BBG00H5H1LL8